Positive Topline Phase III Results for Genentech Vabysmo In Retinal Vein Occlusion

 

• Vabysmo achieved its primary endpoint of non-inferiority compared to aflibercept in RVO in the BALATON and COMINO clinical trials
• Vabysmo was generally well tolerated, with a safety profile consistent with previous trials
• Vabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, linked to a number of vision-threatening retinal conditions
• Detailed results will be presented at an upcoming medical meeting and submitted to regulatory authorities around the world

https://www.biospace.com/article/releases/positive-topline-phase-iii-results-show-genentech-s-vabysmo-improved-vision-for-people-living-with-retinal-vein-occlusion-rvo-/